Korro Bio (KRRO) Current Assets (2018 - 2026)
Korro Bio's (KRRO) quarterly Current Assets came in at $120.2 million in Q1 2026, down 0.88% YoY from $121.2 million in Q1 2025, and up 45.88% on a QoQ basis from $82.4 million in Q4 2025.
Korro Bio (KRRO) Current Assets (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has 9 years of Current Assets data on file, last reported at $120.2 million in Q1 2026.
- Quarterly Current Assets fell 0.88% year-over-year to $120.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $120.2 million (down 0.88% YoY) and the FY2025 annual result came in at $82.4 million, down 37.37% from the prior year.
- Current Assets climbed to $120.2 million in Q1 2026, from $82.4 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $172.7 million in Q4 2023 to a low of $42.5 million in Q3 2023.
- A 5-year average of $108.4 million and a median of $113.4 million in 2022 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets tumbled 57.92% — and 2024, when it soared 259.49%.
- Tracing KRRO's Current Assets over 5 years: stood at $57.1 million in 2022, then jumped by 202.59% to $172.7 million in 2023, then decreased by 23.85% to $131.5 million in 2024, then plunged by 37.37% to $82.4 million in 2025, then surged by 45.88% to $120.2 million in 2026.
- The last three Current Assets figures came in at $120.2 million (Q1 2026), $82.4 million (Q4 2025), and $98.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Korro Bio | 228.60 Mn | 113.56 Mn | - | 120.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 120.63 Mn |
| Mar 31, 2026 | 120.16 Mn |
| Dec 31, 2025 | 82.37 Mn |
| Sep 30, 2025 | 98.23 Mn |
| Jun 30, 2025 | 102.63 Mn |
| Mar 31, 2025 | 121.24 Mn |
| Dec 31, 2024 | 131.53 Mn |
| Sep 30, 2024 | 152.78 Mn |
| Jun 30, 2024 | 163.63 Mn |
| Mar 31, 2024 | 145.66 Mn |
| Dec 31, 2023 | 172.73 Mn |
| Sep 30, 2023 | 42.50 Mn |
| Jun 30, 2023 | 48.38 Mn |
| Mar 31, 2023 | 69.29 Mn |
| Dec 31, 2022 | 57.08 Mn |
| Sep 30, 2022 | 100.99 Mn |
| Jun 30, 2022 | 113.42 Mn |
| Mar 31, 2022 | 119.94 Mn |
| Dec 31, 2021 | 134.75 Mn |
| Sep 30, 2021 | 149.91 Mn |